What's New

Updated June 2021:

  1. Adult Clostridioides difficile infection (CDI) – oral vancomycin prophylaxis for high risk patients with recurrent CDI.

Updated May 2021:

  1. Cefaclor (discontinued in Canada) added to β-lactam cross-reactivity chart for patients who report an allergy in the past.
  2. Changed duration of therapy for mild to moderate community-acquired pneumonia (CAP) to 3 days provided clinical stability criteria are met.
  3. Changed duration of therapy for hand and wrist septic arthritis with surgical drainage to 2 weeks.
  4. Adult central nervous system empiric therapy recommendations.
  5. Adult meningitis culture-directed therapy recommendations.
  6. Addition of culture-directed medical device-associated meningitis/ventriculitis section.

Updated March 2021:

  1. Update of pediatric and adult Genital empiric therapy sections.

Updated January 2021:

  1. Neonatal/pediatric central nervous system empiric therapy recommendations.
  2. Spectrum of activity of doxycycline, macrolides, and quinolones for Mycoplasma and Ureaplasma spp.

Updated November 2020:

  1. Deletion of piperacillin as no longer available in Canada.
  2. Addition of maximum of 3000mg for vancomycin loading dose in adults.
  3. Addition of comprehensive B-lactam cross-reactivity chart and other revisions to cross-reactivity section.

 Updated October 2020:

  1. COVID-19 section.
  2. Addition of amoxicillin–clavulanate IV and fosfomycin IV to Antibiotic sections.

Updated September 2020:

  1. Vancomycin dosing and monitoring guidelines.
  2. Empiric therapy of SSTI in adult patients, particularly B-lactam allergy regimens to decrease use of clindamycin and fluoroquinolones wherever possible.
  3. Empiric therapy of CAP/NHAP/influenza in adult patients.
  4. Culture-directed therapy of Pneumonia in adult patients.